Avid Bioservices Inc (CDMO)

[NP1986]

The PFS of carboplatin-paclitaxel arms is longer in more recent studies:

For example:
http://www.ncbi.nlm.nih.gov/pubmed/22244743
5.9 months (n=59)

http://www.ncbi.nlm.nih.gov/pubmed/21709202
5.5 months (n = 650)

http://www.ncbi.nlm.nih.gov/pubmed/21632509
4.7 months (n = 414)

http://www.ncbi.nlm.nih.gov/pubmed/21532506
4.2 months (n = 55)

http://www.ncbi.nlm.nih.gov/pubmed/21532504
6.3 months (n = 61)

http://www.ncbi.nlm.nih.gov/pubmed/21206386
4.7 months (n = 191)

http://www.ncbi.nlm.nih.gov/pubmed/20100966
4.2 months (n = 338)

http://www.ncbi.nlm.nih.gov/pubmed/19917841
5.0 months (n = 125)

http://www.ncbi.nlm.nih.gov/pubmed/19188680
6.1 months (n = 347)


These are all trials reported in recent years, and some of them were large, multi-center Phase III trials.

PPHM likes to allude to results from a single study that are a decade-old, but I think rational investors should refrain from doing so. If you look at the broader picture, you'll realize that the PFS in the control arm of the bavituximab trial is not an anomaly.